ORGANOGENESIS APLIGRAF SKIN GRAFT PMA APPROVABLE FOR VENOUS ULCERS, PANEL SAYS; PRODUCT EFFECTIVE ONLY FOR WOUNDS MORE THAN ONE YEAR OLD
This article was originally published in The Gray Sheet
Organogenesis's Apligraf (Graftskin) living skin graft is approvable for use in treating partial- and full-thickness skin loss from ulcers of venous etiology, FDA's General and Plastic Surgery Devices Panel concluded in a 5-4 vote at its Jan. 29 meeting in Gaithersburg, Maryland. In recommending approval for the premarket approval application, the advisory committee concurred with company labeling stating that Graftskin is "particularly beneficial" in treating venous ulcers of duration greater than one year.
You may also be interested in...
Organogenesis' Apligraf living skin construct reduces the time it takes diabetic foot ulcers to heal by almost one-third, the company says.
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.